Argus Raises Boston Scientific (BSX) Price Target to $36.00

Argus Raises Boston Scientific (BSX) Price Target to $36.00

Its down 0.38, from 1.34 in 2017Q4. $399,865 worth of Boston Scientific Corporation (NYSE:BSX) shares were sold by Phalen Michael P. The June 35 call is sitting near the top of the list, and data suggests traders are buying to open positions.

Boston Scientific Corporation (BSX)'s RSI (Relative strength index) is at 77.86, its ATR (Average True Range) value is 0.51, while its Beta factor was calculated at 0.78. Additionally, SVP & Pres, Eur, Mid-East, Afr Thepaut Eric Francis Yves sold 20,015 shares of this stock in a transaction that took place on May 17th, 2018. Parametric Associate Lc stated it has 0.09% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Geller Advsr Limited holds 2.76 million shares or 36.77% of its portfolio. Boston Scientific Corporation's institutional ownership is 93.4%, while its institutional transactions stand at -0.08%. Smithfield Trust invested in 0% or 330 shares.

Though it has recently stressed to investors its ability to innovate new technologies, over the years Boston Scientific has grown through acquisitions.

Among 15 analysts covering Boston Scientific Corp (NYSE:BSX), 13 have Buy rating, 0 Sell and 2 Hold. Asset Mgmt Inc invested in 0.12% or 92,622 shares. Hightower Lc accumulated 25,213 shares.

A spokeswoman for Boston Scientific cited a practice of not commenting on "rumors or speculation".

Since December 29, 2017, it had 0 insider purchases, and 20 selling transactions for $9.49 million activity.

Hanseatic Management Services Inc. raised its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 7.8% during the third quarter, Holdings Channel reports. Ballinger Kevin J. had sold 42,803 shares worth $1.21 million. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Mngmt Corporation reported 183,900 shares or 0.05% of all its holdings. Insiders have sold 178,783 shares of company stock worth $5,144,574 over the last ninety days. Truewealth LLC bought a new position in Boston Scientific in the 4th quarter worth $116,000. 14,035,809 shares of the company's stock were exchanged, compared to its average volume of 5,760,389. Morgan Stanley lifted their target price on shares of Boston Scientific from $30.00 to $33.00 and gave the stock an "overweight" rating in a research note on Monday, March 19th.

Shares of NYSE BSX traded up $2.39 during trading on Monday, reaching $34.34. About 14.04M shares traded or 98.82% up from the average. Boston Scientific Corporation (NYSE:BSX)'s Cash Flow to Capex stands at 6.089888. It has underperformed by 1.38% the S&P500.

Fmr Llc, which manages about $842.35 billion US Long portfolio, upped its stake in First Solar Inc (NASDAQ:FSLR) by 711,938 shares to 1.76 million shares, valued at $124.99 million in 2018Q1, according to the filing. During the same quarter in the previous year, the firm earned $0.29 earnings per share. equities research analysts anticipate that Boston Scientific will post 1.39 earnings per share for the current fiscal year. BSX's profit will be $469.14M for 23.49 P/E if the $0.34 EPS becomes a reality. The medical equipment provider reported $0.33 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.32 by $0.01. Suntrust Banks Incorporated holds 0.08% in Boston Scientific Corporation (NYSE:BSX) or 434,113 shares.

More news for Boston Scientific Corporation (NYSE:BSX) were recently published by:, which released: "JANA Shows New Stakes in Apple (AAPL), Boston Scientific (BSX), Dropbox (DBX), iQIYI (IQ) (more.) -13F" on May 15, 2018. Truewealth LLC acquired a new position in shares of Boston Scientific during the fourth quarter worth $116,000. Therefore 81% are positive. The company maintained a Gross Margin of 72.20%. In this case performance of tends to percentage rate of return for a stock for a given time frame. The rating was maintained by Bank of America on Thursday, April 5 with "Buy". Also, EVP David A. Pierce sold 5,000 shares of the business's stock in a transaction dated Friday, June 1st. As per Thursday, July 27, the company rating was maintained by Needham. RBC Capital Markets maintained the shares of BSX in report on Thursday, February 1 with "Buy" rating. Needham maintained the shares of BSX in report on Wednesday, April 25 with "Buy" rating. Boston Scientific shares rose as much as 17%, and jumped 9.5% to $34.99 when trading was halted just before 1 p.m. Monday. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.36 average brokerage recommendation. A report from the Wall Street Journal suggests that the other company has made overtures about striking a deal. Boston Scientific Corporation (BSX) is one of the largest in Healthcare and Medical Appliances & Equipment. Piper Jaffray initiated it with "Buy" rating and $31.0 target in Friday, February 23 report. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg.

Related Articles